USPTO Art Unit 1613 Prosecution Statistics

Art Unit Information

Art Unit: 1613
Group: 1610
Tech Center: 1600
Total Cases: 9,841
Last Active: August 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19302265ALLERGEN DESENSITIZATION METHODAugust 2025December 2025Allow400YesNo
19222659ASSOCIATED FORMS OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND LOCAL ANESTHETICSMay 2025October 2025Allow510NoNo
19210719ORAL SOLID DOSAGE FORMS COMPRISING CANNABINOIDSMay 2025January 2026Allow820YesNo
19175378ENCAPSULATED RESVERATROL (RSV) NANOPARTICLESApril 2025October 2025Allow610NoNo
19175330ENCAPSULATED RESVERATROL (RSV) NANOPARTICLESApril 2025December 2025Allow810NoNo
19173931ENCAPSULATED RESVERATROL (RSV) NANOPARTICLESApril 2025September 2025Allow610NoNo
19174154ENCAPSULATED RESVERATROL (RSV) NANOPARTICLESApril 2025January 2026Allow910NoNo
19094018TESTOSTERONE ENHANCING COMPOSITIONS AND METHODSMarch 2025January 2026Allow1020YesNo
19076524INHIBITION OF CANCER CELL VIABILITYMarch 2025June 2025Allow300NoNo
19068391ORGANIC BIOMATERIAL FOR BONE AND JOINT REPLACEMENTMarch 2025May 2025Allow200NoNo
19061465FORMULATIONS OF BENDAMUSTINEFebruary 2025May 2025Allow310NoNo
19053879LIQUID DEPOT FOR NON-INVASIVE SUSTAINED DELIVERY OF AGENTS TO THE EYEFebruary 2025December 2025Allow1011YesNo
19004832ENCAPSULATED RESVERATROL (RSV) NANOPARTICLESDecember 2024November 2025Allow1111NoNo
18980349MICROPARTICLE FORMULATIONS FOR INTRAVENOUS THERAPY AND METHODS FOR THEIR MANUFACTURE AND USEDecember 2024September 2025Allow920NoNo
18979375Coffee Bean Compositions Comprising Paraxanthine and Methods for Their ProductionDecember 2024February 2025Allow200NoNo
18977228Ribociclib TabletDecember 2024June 2025Allow730YesNo
18873438MUSSEL-INSPIRED PHOTOREACTIVE INSTANT GLUE FOR ENVIRONMENTAL AND BIOMEDICAL APPLICATIONSDecember 2024September 2025Allow1001YesNo
18953665TAMPER RESISTANT DOSAGE FORMSNovember 2024August 2025Abandon920NoNo
18923418CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAMEOctober 2024March 2025Allow510YesNo
18920501INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASEOctober 2024July 2025Allow911YesNo
18899158POLYMERIC IODOPHOR COMPOSITIONS AND METHODS OF USESeptember 2024March 2026Allow1841NoNo
18829557NOVEL LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOFSeptember 2024April 2025Allow710YesNo
18819147DELAYED RELEASE SOFTGEL CAPSULES IN HIGHER PH ENVIRONMENTAugust 2024December 2025Allow1640NoNo
18818363TOPICAL COMPOSITION FOR IMPROVED HEALING OF OPEN WOUNDSAugust 2024April 2025Allow710YesNo
18786785METHOD FOR HYPERTHERMIALLY TREATING A CANCERJuly 2024October 2024Allow210NoNo
18783428COMPOSITIONS CONTAINING CANNABINOID NANOPARTICLESJuly 2024March 2026Allow1900NoNo
18725983DETERMINATION OF THE TRAPPED VOLUME OF A LIPOSOMEJuly 2024February 2026Allow2000NoNo
18758839STABLE NIMODIPINE PARENTERAL FORMULATIONJune 2024March 2025Allow911NoNo
187497322,4-DISUBSTITUTED PYRIDINES AS MALODOR COUNTERACTING INGREDIENTSJune 2024December 2025Abandon1820NoNo
18751134PHENYLEPHRINE HYDROCHLORIDE COMPOSITIONS AND CONTAINERSJune 2024July 2025Allow1331YesNo
18745602SYSTEMS AND METHODS FOR BLENDING SOLID-SHELL COSMETIC INGREDIENT CAPSULES AND BLENDABLE COSMETIC INGREDIENT CAPSULESJune 2024July 2025Abandon1310NoNo
18739378SOLVENT-BASED METHOD FOR MAKING NANOCOMPOSITE PHARMACEUTICAL MATERIALJune 2024August 2024Allow200NoNo
18737162ODOR CONTROL COMPOSITION CONCENTRATESJune 2024March 2025Allow911YesNo
18736621TWO SPEED MONOLITHIC SYSTEM FOR CONTROLLED RELEASE OF DRUGSJune 2024September 2025Abandon1510NoNo
18733139BROMIDE SOURCE FOR USE IN TREATING AUTISM SPECTRAL DISORDERJune 2024July 2025Abandon1410NoNo
18676396ATROPINE-CONTAINING AQUEOUS COMPOSITIONMay 2024December 2025Abandon1820NoNo
18674999LYCOPENE COMPOSITIONS AND METHODS FOR PROTECTING SKIN AGAINST ULTRAVIOLET RADIATIONMay 2024July 2025Allow1420NoNo
18671754FORMULATION OF A RILUZOLE SOLUTION WITH BETA-CYCLODEXTRINSMay 2024September 2025Abandon1601NoNo
18665824ORAL PHARMACEUTICAL COMPOSITION COMPRISING ZONISAMIDE AND PROCESS OF PREPARATION THEREOFMay 2024November 2025Allow1821YesNo
18659232PUTRESCINE TOPICAL BARRIER FORMULATIONMay 2024July 2025Allow1410NoNo
18659332COMBINATION TREATMENT FOR ANTIBIOTIC RESISTANT INFECTIONSMay 2024July 2025Abandon1420NoNo
18658338INTRADIALYTIC USE OF SODIUM NITRITEMay 2024January 2026Allow2010NoNo
18658056LIQUID CRYSTALLINE DOSAGE FORM FOR ADMINISTERING A STATINMay 2024September 2025Allow1620NoNo
18647063COLOR STABLE SKIN BENEFIT COMPOSITIONSApril 2024July 2025Allow1510NoNo
18646171FORMULATIONS OF BENDAMUSTINEApril 2024August 2024Allow410NoNo
18646329FORMULATIONS OF BENDAMUSTINEApril 2024April 2025Allow1220NoNo
18643086FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATEApril 2024May 2025Allow1320NoNo
186418484-[4,5-BIS(4-BROMOPHENYL)-1-HEXYL-1H-IMIDAZOL-2-YL]ISOQUINOLIN-3-OL AS AN ANTIMICROBIAL COMPOUNDApril 2024October 2024Allow610NoNo
186418454-[4,5-BIS(4-BROMOPHENYL)-1-HEXYL-1H-IMIDAZOL-2-YL]ISOQUINOLIN-3-OL AS AN ANTIMICROBIAL COMPOUNDApril 2024October 2024Allow610NoNo
18637772INJECTABLE SLURRIES AND METHODS OF MANUFACTURING THE SAMEApril 2024August 2025Abandon1610NoNo
18637263COMPOSITIONS, FORMULATIONS AND METHODS FOR STIMULATING RESPIRATIONApril 2024December 2025Abandon2021YesNo
18632164PAINLESS NGF FOR FRACTURE REPAIRApril 2024May 2025Abandon1310NoNo
18630735METHOD FOR MANUFACTURING BONE-REGENERATION MATERIAL COMPRISING BIODEGRADABLE FIBERS BY USING ELECTROSPINNING METHODApril 2024March 2026Allow2300NoNo
18629406METHOD AND KIT FOR BOWEL PREPARATIONApril 2024April 2025Allow1210YesNo
18629364Pharmaceutical Composition And Method For Treating Seizure DisordersApril 2024February 2026Abandon2321NoNo
18626675METHODS FOR IMPROVING RESPIRATORY SYSTEM HEALTH AND INCREASING THE CONCENTRATION OF HYPOTHIOCYANATE ION IN VERTEBRATE LUNGSApril 2024July 2025Allow1610YesNo
18624804Personal Care FormulationsApril 2024April 2025Allow1210NoNo
18616858Cannabinoid PouchMarch 2024February 2025Allow1110NoNo
186165772-(BENZO[D]THIAZOL-2-YL)-N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDMarch 2024September 2024Allow610NoNo
186166032-(BENZO[D]THIAZOL-2-YL)-N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDMarch 2024August 2024Allow510NoNo
18612888CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLESMarch 2024May 2025Allow1400YesNo
18693714URIC ACID LIPOSOMESMarch 2024December 2025Allow2100YesNo
18603884TAMPER RESISTANT DOSAGE FORMSMarch 2024July 2024Allow430NoNo
18602981PHARMACEUTICAL CAPSULES COMPRISING LUMATEPERONE MONO-TOSYLATEMarch 2024September 2024Allow610NoNo
18599893HIGH STEROL-CONTAINING LIPID NANOPARTICLESMarch 2024April 2025Allow1320YesNo
18598402Devices for Treating Diseases and ConditionsMarch 2024May 2024Allow200YesNo
18599125METHOD OF TREATING DISEASESMarch 2024January 2025Allow1020YesNo
18599127METHOD OF TREATING DISEASESMarch 2024January 2025Allow1020NoNo
18598292WOOD TREATMENT SOLUTIONS CONTAINING FUNGICIDES AND TERTIARY ALKANOLAMINES AND RELATED METHODS, WOOD PRODUCTS AND COMPOSITION FOR PROTECTION AGAINST FUNGAL ORGANISMSMarch 2024July 2025Allow1720NoNo
18594725MODULATORS OF TNF-ALPHA ACTIVITYMarch 2024February 2025Allow1100YesNo
18594231OCULAR LUBRICANT FORMULATIONSMarch 2024August 2025Allow1710NoNo
18587736EMBOLIC COMPOSITIONSFebruary 2024April 2025Allow1310YesNo
18583383OCULAR HYDROGEL TYROSINE KINASE INHIBITOR IMPLANTSFebruary 2024February 2026Abandon2430NoNo
18582320PHARMACEUTICAL COMPOSITIONS OF DIMETHYL FUMARATEFebruary 2024June 2025Allow1611NoNo
18444175ENHANCED IMMUNE RESPONSE UPON TREATMENT WITH NITRIC OXIDEFebruary 2024April 2025Abandon1410NoNo
18443353PERSONAL CARE COMPOSITION COMPRISING WATER INSOLUBLE SOLID ORGANIC COMPOUNDFebruary 2024September 2024Allow700YesNo
18441930ALLERGEN DESENSITIZATION METHODFebruary 2024May 2025Allow1510YesNo
18439468PHARMACEUTICAL COMPOSITIONS OF ALPHA-2-ADRENERGIC RECEPTOR AGONISTS AND THEIR USE FOR IMPROVING VISIONFebruary 2024July 2025Abandon1701NoNo
18437368CAPSULE FORMULATIONSFebruary 2024April 2025Abandon1410NoNo
18436814Method for Synthesizing Selenium Nanoparticles from Edible MushroomsFebruary 2024April 2025Abandon1420NoNo
18436404Method for Synthesizing Selenium Nanoparticles from Edible MushroomsFebruary 2024March 2025Abandon1320NoNo
18435678EFLORNITHINE AND SULINDAC, FIXED DOSE COMBINATION FORMULATIONFebruary 2024March 2025Allow1310YesNo
18681556PREPARATION OF COMPOSITE GELS, POLYMER SCAFFOLDS, AGGREGATES AND FILMS COMPRISING SOLUBLE CROSS-LINKED CHITOSAN & USES THEREOFFebruary 2024May 2025Allow1521YesNo
18432404PROCESSES FOR MAKING CYCLIC LIPID IMPLANTS FOR INTRAOCULAR USEFebruary 2024February 2026Abandon2411NoNo
18431035PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCERFebruary 2024April 2025Allow1410NoNo
18431490LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTSFebruary 2024November 2025Allow2110NoNo
18429916METHODS OF PEST CONTROL IN SOYBEANFebruary 2024June 2025Allow1710NoNo
18427459CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAMEJanuary 2024July 2024Allow610NoNo
18426704TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTSJanuary 2024April 2025Abandon1510NoNo
184262119-(6-FLOURO-2-HYDROXYPYRIDIN-3-YL)-10-(2-HYDROXYETHYL)-3,6-DIPHENYL-3,4,6,7,9,10-HEXAHYDROACRIDINE1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUNDJanuary 2024September 2024Allow710NoNo
184260929-(6-FLOURO-2-HYDROXYPYRIDIN-3-YL)-10-(2-HYDROXYETHYL)-3,6-DIPHENYL-3,4,6,7,9,10-HEXAHYDROACRIDINE1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUNDJanuary 2024August 2024Allow710NoNo
18421265NITRIC OXIDE THERAPIESJanuary 2024January 2026Allow2420NoNo
184215352-[(1,3-BENZOTHIAZOL-2-YL)IMINO]-5,5-DIPHENYLIMIDAZOLIDIN-4-ONE AS AN ANTIMICROBIAL COMPOUNDJanuary 2024September 2024Allow811NoNo
18580703BIOMIMETIC, REACTIVE OXYGEN SPECIES-DETONABLE NANOCLUSTERS FOR ANTIRESTENOTIC THERAPYJanuary 2024January 2026Allow2410NoNo
18414411BIODEGRADABLE POLYMER FINE PARTICLE FOR FILLER, FREEZE-DRIED BODY INCLUDING THE SAME, MANUFACTURING METHOD THEREOF, AND FILLER INJECTION INCLUDING FREEZE-DRIED BODYJanuary 2024March 2026Allow2631YesNo
18414007PROCESS FOR THE MANUFACTURE AND USE OF PANCREATIN MICROPELLET CORESJanuary 2024February 2026Abandon2540YesNo
18411482IMMUNISATION OF LARGE MAMMALS WITH LOW DOSES OF RNAJanuary 2024November 2025Allow2200NoNo
18412318COMPOSITIONS AND METHODS FOR THEIR PRODUCTIONJanuary 2024September 2024Allow810NoNo
18408463METHODS OF USE OF EMULSION FORMULATIONS OF APREPITANTJanuary 2024January 2025Allow1320NoNo
18406793Cardiovascular ProsthesesJanuary 2024December 2025Abandon2320NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1613.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
384
Examiner Affirmed
285
(74.2%)
Examiner Reversed
99
(25.8%)
Reversal Percentile
17.5%
Lower than average

What This Means

With a 25.8% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
1358
Allowed After Appeal Filing
251
(18.5%)
Not Allowed After Appeal Filing
1107
(81.5%)
Filing Benefit Percentile
4.2%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 18.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1613 - Prosecution Statistics Summary

Executive Summary

Art Unit 1613 is part of Group 1610 in Technology Center 1600. This art unit has examined 9,841 patent applications in our dataset, with an overall allowance rate of 49.2%. Applications typically reach final disposition in approximately 32 months.

Comparative Analysis

Art Unit 1613's allowance rate of 49.2% places it in the 7% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1613 receive an average of 2.43 office actions before reaching final disposition (in the 85% percentile). The median prosecution time is 32 months (in the 40% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for multiple rounds of prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.